Q Biomed Inc

Q Biomed Inc. Modifies Over 3.6 Million Warrants, Reclassifies Equity to Liability

Track all markets on TradingView Q Biomed Inc. (QBIO), a biomedical acceleration and development company, updated its financial records to include the modification of an aggregate of 3,608,641 warrants originally granted to certain officers during 2017 and 2021. The exercise price of the warrants was reduced to $0.10 per share, resulting in an immediate recognition …

Q Biomed Inc. Modifies Over 3.6 Million Warrants, Reclassifies Equity to Liability Read More »

Q Biomed Inc. Secures $100,000 from 400,000-Unit Private Placement

Track all markets on TradingView Q Biomed Inc. (QBIO), a leading biotechnology accelerator, has recently secured $100,000 in funding through the issuance of 400,000 units in a private placement. Each unit comprises one common share and one warrant to purchase common stock at an exercise price of $0.50. The successful placement demonstrates the company’s ability …

Q Biomed Inc. Secures $100,000 from 400,000-Unit Private Placement Read More »

Q Biomed Inc’s Metastron First Commercial Sale Commences Following Transfer of Intellectual Property and New Manufacturing Site Establishment

Track all markets on TradingView Q Biomed Inc (QBIO) announced that the first commercial sale of Metastronβ„’ is set to happen following the successful transfer or assignment of all intellectual property, material sales and distribution data, technical transfer, and the establishment of new manufacturing sites under the appropriate regulatory filings required. This development marks a …

Q Biomed Inc’s Metastron First Commercial Sale Commences Following Transfer of Intellectual Property and New Manufacturing Site Establishment Read More »

Q BioMed Inc.’s Q1 2023 net loss increases while exploring licensing and acquisitions

Track all markets on TradingView Q BioMed Inc. (QBMG), a biomedical acceleration and development company, released its financial report for Q1 2023, revealing a net loss of $721,612 that is larger than the net loss of $2,288,623 observed during the same period last year. Despite the increased net loss, the company continues to focus on …

Q BioMed Inc.’s Q1 2023 net loss increases while exploring licensing and acquisitions Read More »

Q Biomed Inc. Reports Unaudited Financial Statements for the Quarter Ended February 2023

Track all markets on TradingView Q Biomed Inc. (QBIO), a biotechnology company focused on addressing unmet medical needs through innovations and acquisitions in healthcare, has recently submitted its unaudited financial statements for the quarter ended February 28, 2023. The company acknowledges that the financial statements included in the Form 10-Q have not been independently reviewed …

Q Biomed Inc. Reports Unaudited Financial Statements for the Quarter Ended February 2023 Read More »

Q Biomed Inc. Reports Decrease in Sales and Reduced Operating Expenses for Q3

Track all markets on TradingView Q Biomed Inc. (QBIO), a biotechnology company specializing in the development of pharmaceutical products, has released its financial results for the third quarter ended February 28, 2023. The key highlights of the report include a decrease in sales revenues for their Strontium89 product, a reduction in operating expenses, and ongoing …

Q Biomed Inc. Reports Decrease in Sales and Reduced Operating Expenses for Q3 Read More »

Q Biomed Inc. Converts $238,000 of Outstanding Debt into Shares, Issues 1,000,000 Series C Preferred Stocks

Track all markets on TradingView Q Biomed Inc. (QBIO), a commercial-stage biomedical development company, has been focused on maintaining its pipeline and seeking strategic capital or business partnerships and merger opportunities amid capital challenges. According to the company’s quarterly report, QBIO successfully converted approximately $238,000 of outstanding debt and interest into 33,823,234 shares of common …

Q Biomed Inc. Converts $238,000 of Outstanding Debt into Shares, Issues 1,000,000 Series C Preferred Stocks Read More »

Q Biomed Inc. Defaults on July Debenture, Continues Debt Conversions

Track all markets on TradingView Q Biomed Inc. (QBIO), a biotechnology company focused on innovative healthcare, currently finds itself in default on its July Debenture. Despite this setback, the company has continued to convert outstanding debts and extinguish embedded derivative liabilities throughout its fiscal year, which ended on November 30, 2022. This article will explore …

Q Biomed Inc. Defaults on July Debenture, Continues Debt Conversions Read More »

Q Biomed Inc. Reports Increase in Dilutive Securities and Significant Debt Status in Latest Quarterly Report

Track all markets on TradingView Q Biomed Inc. (QBIO), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics, recently released its quarterly report. The report highlights several noteworthy aspects of the company’s financial performance, including an increase in potentially dilutive securities and significant outstanding debt. Q Biomed Inc.’s potentially dilutive securities grew to …

Q Biomed Inc. Reports Increase in Dilutive Securities and Significant Debt Status in Latest Quarterly Report Read More »

Q Biomed Inc. Reports Net Loss of $721,612 in Q2 Financials

Track all markets on TradingView Q Biomed Inc. (ticker: QBIO) recently submitted a quarterly report for the period ending February 28, 2023. The company, which focuses on licensure, acquisition, and strategic resources for life sciences and healthcare companies, reported a net loss of $721,612, accompanied by total current assets of $33,981 and an accumulated deficit …

Q Biomed Inc. Reports Net Loss of $721,612 in Q2 Financials Read More »